ATE328006T1 - Neues protein und verfahren zu dessen herstellung - Google Patents

Neues protein und verfahren zu dessen herstellung

Info

Publication number
ATE328006T1
ATE328006T1 AT98914034T AT98914034T ATE328006T1 AT E328006 T1 ATE328006 T1 AT E328006T1 AT 98914034 T AT98914034 T AT 98914034T AT 98914034 T AT98914034 T AT 98914034T AT E328006 T1 ATE328006 T1 AT E328006T1
Authority
AT
Austria
Prior art keywords
protein
substance
antibody
dna
preparing
Prior art date
Application number
AT98914034T
Other languages
English (en)
Inventor
Kyoji Yamaguchi
Hisataka Yasuda
Nobuaki Nakagawa
Nobuyuki Shima
Masahiko Kinosaki
Eisuke Tsuda
Masaaki Goto
Kazuki Yano
Akihiro Tomoyasu
Fumie Kobayashi
Naohiro Washida
Ken Takahashi
Tomonori Morinaga
Kanji Higashio
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE328006(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE328006T1 publication Critical patent/ATE328006T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
AT98914034T 1997-04-15 1998-04-15 Neues protein und verfahren zu dessen herstellung ATE328006T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02

Publications (1)

Publication Number Publication Date
ATE328006T1 true ATE328006T1 (de) 2006-06-15

Family

ID=27525882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98914034T ATE328006T1 (de) 1997-04-15 1998-04-15 Neues protein und verfahren zu dessen herstellung

Country Status (21)

Country Link
US (7) US7527790B2 (de)
EP (3) EP2336168A1 (de)
JP (7) JP3523650B2 (de)
KR (1) KR100496063B1 (de)
CN (1) CN1138786C (de)
AT (1) ATE328006T1 (de)
AU (1) AU735355B2 (de)
CA (2) CA2257247C (de)
CY (1) CY2010017I2 (de)
DE (2) DE122010000049I1 (de)
DK (1) DK0911342T4 (de)
ES (1) ES2263204T5 (de)
FR (1) FR10C0048I2 (de)
HU (3) HU229841B1 (de)
IL (1) IL127115A (de)
LU (1) LU91759I2 (de)
NO (2) NO322632B1 (de)
NZ (1) NZ332995A (de)
PT (1) PT911342E (de)
RU (1) RU2238949C2 (de)
WO (1) WO1998046644A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
EP1995318A1 (de) 1996-12-13 2008-11-26 Schering Corporation Säugerzelloberflächenantigene und damit zusammenhängende Reagenzien
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
WO1998046644A1 (en) 1997-04-15 1998-10-22 Snow Brand Milk Products Co., Ltd. Novel protein and process for producing the same
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ES2317694T3 (es) * 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
AU755422B2 (en) 1998-10-28 2002-12-12 Sankyo Company Limited Remedies for bone metabolic errors
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) † 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
WO2002081521A2 (en) 2001-04-03 2002-10-17 Société des Produits Nestlé S.A. Osteoprotegerin in milk
CN103232539B (zh) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
CA2508773C (en) * 2002-12-10 2013-08-27 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
MXPA06001353A (es) 2003-08-08 2006-05-04 Abgenix Inc Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos.
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005068503A2 (en) 2004-01-07 2005-07-28 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2007093050A1 (en) * 2006-02-13 2007-08-23 Olga Ornatsky Gene expression assays conducted by elemental analysis
CA2651597C (en) 2006-05-12 2013-02-05 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
JP5191390B2 (ja) 2006-10-11 2013-05-08 オリエンタル酵母工業株式会社 可溶型ｒａｎｋｌとエピトープタグの融合タンパク質を含む試薬
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
CN101772351B (zh) 2007-06-05 2013-01-02 东方酵母工业株式会社 新的骨量增加药
EP2907826B1 (de) 2007-10-11 2018-05-30 Daiichi Sankyo Company, Limited Auf das osteoklastenabhängige protein siglec-15 gerichteter antikörper
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
JP2012520098A (ja) * 2009-03-30 2012-09-06 エフ．ホフマン−ラ ロシュ アーゲー ガラスの曇りを防ぐための方法
RU2539790C2 (ru) 2009-04-09 2015-01-27 Дайити Санкио Компани, Лимитед АНТИТЕЛО ПРОТИВ Siglec-15
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
EP2434285A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebsdiagnose
CN103237813A (zh) 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体
JPWO2012050154A1 (ja) * 2010-10-13 2014-02-24 学校法人東京女子医科大学 抗ｖｄａｃ抗体を含有する破骨細胞形成抑制剤
CA2831247C (en) 2011-03-31 2020-07-21 Oriental Yeast Co., Ltd. Cancer immunopotentiating agent containing rankl antagonist
WO2013142186A1 (en) * 2012-03-21 2013-09-26 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
MX2014011828A (es) 2012-03-30 2014-12-10 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
KR20150036274A (ko) 2012-07-19 2015-04-07 알레시아 바이오쎄라퓨틱스 인코포레이티드 항-siglec-15 항체
CN102788817B (zh) * 2012-08-24 2015-04-08 中煤科工集团重庆研究院有限公司 超低温环境下可燃气体爆炸特性实验研究方法
AU2014305111B2 (en) 2013-08-07 2019-05-30 Fertilitypro Aps Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
US10357559B2 (en) 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
BR112019004901A2 (pt) * 2016-09-13 2019-06-25 E&S Healthcare Co Ltd anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN111205354B (zh) * 2020-01-22 2021-01-22 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其构建方法与用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
CA2071912C (en) 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69427588T2 (de) 1993-09-14 2002-04-25 Merck & Co Inc HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
EP0727211A1 (de) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Verwendung von src SH2-spezifische Verbindungen zur Behandlung von Knochenresorptionserkrankungen
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP1995318A1 (de) 1996-12-13 2008-11-26 Schering Corporation Säugerzelloberflächenantigene und damit zusammenhängende Reagenzien
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998046644A1 (en) * 1997-04-15 1998-10-22 Snow Brand Milk Products Co., Ltd. Novel protein and process for producing the same
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ES2317694T3 (es) 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
CN103232539B (zh) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.

Also Published As

Publication number Publication date
FR10C0048I1 (de) 2011-01-14
KR100496063B1 (ko) 2005-06-21
LU91759I2 (fr) 2011-01-24
US20030176647A1 (en) 2003-09-18
HUS1400027I1 (hu) 2016-10-28
AU735355B2 (en) 2001-07-05
DE69834699T3 (de) 2013-11-14
EP0911342B1 (de) 2006-05-31
JP4230993B2 (ja) 2009-02-25
US7449185B2 (en) 2008-11-11
NO322632B1 (no) 2006-11-06
CN1222917A (zh) 1999-07-14
LU91759I9 (de) 2019-01-02
CA2257247A1 (en) 1998-10-22
AU6851898A (en) 1998-11-11
ES2263204T5 (es) 2013-10-14
NO2010021I2 (no) 2015-03-09
ES2263204T3 (es) 2006-12-01
JP3935861B2 (ja) 2007-06-27
NZ332995A (en) 2000-07-28
KR20040004509A (ko) 2004-01-13
US20030208045A1 (en) 2003-11-06
JP2004041195A (ja) 2004-02-12
DK0911342T3 (da) 2006-08-21
EP1657255A1 (de) 2006-05-17
US20120329671A1 (en) 2012-12-27
JP2005176847A (ja) 2005-07-07
AU735355C (en) 1998-11-11
NO2010021I1 (no) 2011-01-10
NO985848D0 (no) 1998-12-14
CY2010017I1 (el) 2011-02-02
IL127115A (en) 2013-08-29
HU229476B1 (en) 2014-01-28
US20100136011A1 (en) 2010-06-03
JP2009013177A (ja) 2009-01-22
PT911342E (pt) 2006-08-31
EP0911342A4 (de) 2002-11-27
JP2013139465A (ja) 2013-07-18
DE69834699T2 (de) 2007-05-16
DE122010000049I1 (de) 2011-05-05
CA2257247C (en) 2012-09-11
EP1657255B1 (de) 2014-07-30
US20070009520A1 (en) 2007-01-11
HUP0000717A2 (hu) 2000-06-28
HU229841B1 (en) 2014-09-29
IL127115A0 (en) 1999-09-22
JP2012041345A (ja) 2012-03-01
JP5285751B2 (ja) 2013-09-11
DE69834699D1 (de) 2006-07-06
EP2336168A1 (de) 2011-06-22
JP4878616B2 (ja) 2012-02-15
US20080187540A9 (en) 2008-08-07
HU0800628D0 (en) 2010-06-28
DK0911342T4 (da) 2013-07-29
JP3523650B2 (ja) 2004-04-26
EP0911342B2 (de) 2013-05-22
US20050003457A1 (en) 2005-01-06
CA2781623A1 (en) 1998-10-22
JP5593407B2 (ja) 2014-09-24
US7527790B2 (en) 2009-05-05
US20050208580A1 (en) 2005-09-22
NO985848L (no) 1999-02-15
US7192718B2 (en) 2007-03-20
RU2238949C2 (ru) 2004-10-27
CY2010017I2 (el) 2012-01-25
JP4355357B2 (ja) 2009-10-28
CN1138786C (zh) 2004-02-18
EP0911342A1 (de) 1999-04-28
WO1998046644A1 (en) 1998-10-22
JP2009029834A (ja) 2009-02-12
FR10C0048I2 (fr) 2013-08-16

Similar Documents

Publication Publication Date Title
ATE328006T1 (de) Neues protein und verfahren zu dessen herstellung
ES2059298T3 (es) Adn que codifica receptores humanos de 5-ht1d y utilizaciones del mismo.
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ES2173922T3 (es) Polipeptidos de la familia del gen de la semaforina.
EP1717315A3 (de) Osteoprotegerin bindende Proteine und Rezeptoren
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE50015156D1 (de) Gegen Procalcitonin gerichtete Antikörper, ihre Herstellung und Verwendung
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
ATE331027T1 (de) Massgeschneiderte peptidsynthetasen, verfahren zu ihrer herstellung und ihre verwendung
DE69637941D1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
ATE203271T1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
ATE190630T1 (de) Angiotensin-ii typ-1 rezeptor und dessen herstellung
DE69738302D1 (de) Neues semaphorin-gen: semaphorin y
WO2001064876A3 (en) Human schizophrenia gene
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
ATE376000T1 (de) Proteine mit hoher immunreaktivität sowie ein verfahren zu ihrer herstellung
ATE556135T1 (de) Neues protein
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
EP1482038A4 (de) Neues protein und seine dna